Evaluation shows genetic diagnosis may guide antisense oligonucleotide treatment protocols for epilepsy.
This study evaluates the proportion of established antisense oligonucleotides (ASO) assessment guidelines that are amenable to ASO therapy approaches for genetically diagnosed infants.
No takes yet. Share an insight, caveat, or question.
Sherrill et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: